All your recent talking is just nonsense in the grand scheme of bringing the strength of DCVax platform into full play, with the most important and critical step of showing DCVax-L is effective and safe in treating GBM patients, thus showing the concept/MOA works
And that will be known within a short period of time after DL.
Investors buy stock based on both the potentials and fully diluted share counts of the underlining stock.
If the topline data shows the approval of concept, nothing you have talked about recently will make any sense.
Don't think those 200 million warrant/option holders are idiot who would be in a rush to exercise and lock profit; yes some of them would exercise part of it due to not fear of losing profit, but strategic and tactic reasons based on the situations of their individual portfolios.
When the whole market, or a big chunk of it, is salivating the huge potentials of DCVax platform, which has become a pretty much a sure thing, think what you have spewed in this board recently. That kind of talking doesn't make any sense.
Of course, people should lighten their positions if they don't believe the chance of success of DCVax-l, or rebalance their positions if they don't want to take too much of risks. All those are normal part of stock investment, particularly small biotech investment in the face of a binary event.
BTW, if warrant holders want to renegotiate an extension with the company, the company should decline because they would want to get more of it, and they already got too much at the cost of retails.
Don't think the market is stupid, which would not understand what the implications are if DCVax-L is shown both safe and efficacious in treating GBM patients.
Faced with the success, on which stock exchanges is our stock traded is really not that important. Any institutional funds will easily find a way to get around any hurdles if any, and onboard.
